bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P5-14-17: Musculoskeletal side effects over time and association with adherence in women taking neoadjuvant letrozole for estrogen receptor positive DCIS: CALGB 40903 (Alliance)
Authors: Kimmick Gretchen , Dueck Amylou C , Shelby Rebecca , Naughton Michelle , Caudle Abigail , Fruth Briant , Hwang E. Shelley 
Published: March 2020

Abstract
Background: Side effects of and adherence to aromatase inhibitors in women with ductal carcinoma in situ are not well described. Methods: Postmenopausal women in a prospective phase II study of neoadjuvant letrozole for estrogen receptor positive DCIS completed questionnaires on side effects [Menopause Specific Quality of Life Questionnaire (MENQOL), Brief Pain Inventory-short form (BPI-SF), Arthritis Impact Measurement Scales (AIMS2)], well-being (FACT-G), and adherence [Medication-Taking questionnaire] at baseline, 1, 3 and 6 months (mo), and study completion. We used descriptive statistics and paired t-tests to compare 1, 3 and 6 mo results to baseline. Hierarchical linear mixed modeling, controlling for baseline symptom or well-being level, was used to examine effect of symptoms and well-being on intentional and nonintentional nonadherence, based on the Medication-Taking Questionnaire. Results: Included were 84 women, mean age 63 (39-83) years. In univariate analyses, compared to baseline, menopausal symptoms increased [physical (p=0.001 at 3, p&lt;0.001 at 6 mo); vasomotor (p&lt;0.001 at 1, 3, 6 mo), psychosocial (p=0.006 at 6 mo) and sexual (p=0.01 at 6 mo)]. Joint pain and stiffness increased [BPI-SF pain subscale (p=0.048 at 3, p=0.01 at 6 mo); AIMS2 joint pain subscale (p=0.03 at 1, p&lt;0.001 at 3 and 6 mo); AIMS2 stiffness subscale (p=0.004 at 3, p=0.01 at 6 mo)]. Intentional and nonintentional adherence did not significantly change over time (p&gt;0.05). Lower emotional (p=0.049) and functional (p=0.002) well-being by FACT-G and higher joint pain (p=0.03) by AIMS2 were associated with higher nonintentional nonadherence; higher physical side effects of menopause (p=0.001) by MENQOL were associated with lower intentional nonadherence. Conclusions: Among women taking letrozole for DCIS, menopausal symptoms and joint pain/stiffness increased over time with most differences noted at 3 and 6 mo. Lower well-being and higher symptom levels were associated with higher nonintentional nonadherence. NCT01439711.U10CA180821, U10CA180882, UG1CA189823, Breast Cancer Research Foundation, https://acknowledgments.alliancefound.org.
Citation Format: Gretchen Kimmick, Amylou C Dueck, Rebecca Shelby, Michelle Naughton, Abigail Caudle, Briant Fruth, E. Shelley Hwang. Musculoskeletal side effects over time and association with adherence in women taking neoadjuvant letrozole for estrogen receptor positive DCIS: CALGB 40903 (Alliance) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-14-17.
Abstract P6-03-14: Conditional reprogrammed cells enable us to examine the drug resistance for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer
Authors: Mimoto Rei , Yogosawa Satomi , Fushimi Atsushi , Nogi Hiroko , Asakura Tadashi , Yoshida Kiyotsugu , Takeyama Hiroshi 
Published: March 2020

Abstract
Objectives: Various new drugs have been developed for treating recurrent hormone receptor-positive/human epidermal receptor 2-negative breast cancer. However, directly identifying effective drugs remains difficult. In this study, we elucidated the clinical relevance of cultured cells derived from patients with recurrent hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer. Methods: We generated conditional reprogrammed cells from primary and metastatic breast cancer. CR cells were co-cultured with irradiated mouse fibroblast feeder cells in the presence of the Rho kinase inhibitor Y-27632. We performed microarray analysis using a SurePrint G3 Human GE microarray kit Ver. 2.0, and DNA target sequence using QIAseq Targeted DNA Panels to analyze the genetic variants of the 93 most commonly mutated genes in human breast cancer samples. We examined the pathological features by xenograft model. For drug screening assay, we used Cambridge Cancer Compound Library. Results: The results of microarray analysis, DNA target sequencing and xenograft experiments indicated that the mutation status and pathological features were preserved in CR cells, whereas RNA expression was different from that in the primary tumor cells, especially with respect to cell adhesion-associated pathways. The results of drug sensitivity assays involving the use of primary breast cancer CR cells were consistent with the result of Oncotype Dx. We performed drug screening assays using liver metastases, which were sensitive to 66 drugs. The result reflected the actual clinical course of this patient, resistant to taxanes and sensitive to fulvestrant plus palbociclib. Conclusion: These results supported the use of CR cells obtained from the metastatic lesions of patients with HR+/HER2− breast cancer for predicting the clinical drug efficacy.
Citation Format: Rei Mimoto, Satomi Yogosawa, Atsushi Fushimi, Hiroko Nogi, Tadashi Asakura, Kiyotsugu Yoshida, Hiroshi Takeyama. Conditional reprogrammed cells enable us to examine the drug resistance for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-03-14.
Abstract P6-03-19: Oridonalogs reverse chemoresistance in breast cancer cells by targeting STAT3
Authors: Liu Xi , Wen Yefei , Kim Hyejin , Wang Pingyuan , Chen Haiying , Hu Mingdao , Ding Ye , Zhou Jia , Shen Qiang 
Published: March 2020

Abstract
Chemotherapy remains the mainstream treatment option for invasive and metastatic breast cancer. Adriamycin (ADR) is one of the most frequently used and an effective chemotherapeutic agent for treating patients with breast cancer. However, the resistance towards ADR becomes a major obstacle to achieve efficacy and favorable outcomes in breast cancer patients with chemotherapy. We recently developed a serial oridonalogs that may possess the ability to overcome chemoresistance in cancer cells, whereas whether these novel anti-cancer agents reverse ADR resistance in resistant breast cancer cells are not adequately explored and further the mechanism of action has not been studied. In this study, oridonalogs, YD0514, CYD0618, and CYD0686, were used to determine their effects on the proliferation of the ADR-resistant breast cancer cells. We found significant inhibition of proliferation of wild-type breast cancer cell line MCF-7 and ADR-resistant MCF-7/ADR cells, time- and dose-dependently. Among the tested compounds, CYD0618 and CYD0686 were more effective in inducing apoptosis in wild-type and resistant breast cancer cells than YD0514, in comparison to the natural product and lead compound oridonin. In addition, total STAT3 level was found higher in ADR-resistant breast cancer cells, while phospho-STAT3 was higher in resistant cells. CYD0618 inhibited STAT3 activation in ADR-resistant cells. Our findings suggest that STAT3 activation may be critically involved in the development of acquired resistance to ADR, while oridonalogs such as CYD0618 may open the avenue to reverse and overcome ADR resistance in breast cancer by targeting STAT3. Further mechanistic explorations are currently underway.
Citation Format: Xi Liu, Yefei Wen, Hyejin Kim, Pingyuan Wang, Haiying Chen, Mingdao Hu, Ye Ding, Jia Zhou, Qiang Shen. Oridonalogs reverse chemoresistance in breast cancer cells by targeting STAT3 [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-03-19.
Abstract P6-03-24: ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in triple-negative breast cancer
Authors: Zhou Haiying , Ye Qiuping , Pankov Aleksandr , Kong Wayne , Barkund Shravani , Friedman Lori S. , Sun Jessica D. , Kabbarah Omar 
Published: March 2020

Abstract
ORIC-101 is a novel and selective glucocorticoid receptor (GR) antagonist currently in Ph1 clinical evaluation in solid tumors. In preclinical models, ORIC-101 potently sensitized triple-negative breast cancer (TNBC) cells to chemotherapy by inhibiting GR-mediated resistance through the epithelial-to-mesenchymal transition and anti-apoptosis pathways, both in vitro and in vivo. To inform the clinical development of ORIC-101, we identified pharmacodynamic (PD) biomarkers and established a relationship between those biomarkers, pharmacokinetics (PK), and efficacy in preclinical models. Using genome-wide profiling, we developed a GR activation signature that includes the direct GR transcriptional targets FKBP5 and GILZ, and subsequently validated both genes as ORIC-101 PD biomarkers in a panel of cell lines. We demonstrated that FKBP5 and GILZ are transcriptionally induced by glucocorticoids in a dose-dependent manner, and that the degree of their transcriptional activation is correlated with basal levels of GR in these models. We showed that ORIC-101 robustly inhibits the transcriptional induction of FKBP5 and GILZ and fully reverses GR-mediated chemoresistance in vitro and in vivo. Furthermore, FKBP5 and GILZ are reliable PD biomarkers for ORIC-101 in human-derived peripheral blood mononuclear cells (PBMCs). Importantly, by integrating PK, PD, and efficacy results from numerous preclinical studies, we captured the relationship between ORIC-101 PK, PD biomarker modulation, and chemopotentiation. Altogether, FKBP5 and GILZ mRNA levels are robust PD biomarkers to measure GR pathway engagement and modulation which corresponds with efficacy in response to GR antagonist treatment in preclinical models. These findings will guide the clinical development of ORIC-101 in TNBC.
Citation Format: Haiying Zhou, Qiuping Ye, Aleksandr Pankov, Wayne Kong, Shravani Barkund, Lori S. Friedman, Jessica D. Sun, Omar Kabbarah. ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in triple-negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-03-24.
Abstract P6-04-25: Epidermal growth factor receptor as therapeutic target in hormone receptor-positive breast cancer
Authors: Jeong Yisun , Bae Soo Youn , You Daeun , Jung Seung Pil , Choi Hee Jun , Kim Isaac , Lee Se Kyung , Yu Jonghan , Kim Seok Won , Lee Jeong Eon , Kim Sangmin , Nam Seok Jin 
Published: March 2020

Abstract
Background/Aims: Despite effective therapeutic strategies for treating hormone receptor-positive (HR+) breast cancer, resistance to endocrine therapy that is either de novo or acquired still occurs. We investigated epidermal growth factor receptor (EGFR) as a therapeutic target for overcoming endocrine resistance in HR+ breast cancer models. Methods: Using clinical data from 2,166 patients who had HR+ breast tumors and received tamoxifen, we analyzed survival rates. Levels of mRNA and protein expression were analyzed by real-time PCR and western blotting, respectively. Cell viability was analyzed by MTT assays and anchorage-independent growth by soft agar colony-formation assays. Efficacy of tamoxifen and/or gefitinib was analyzed using orthotopic xenograft mouse models. Results: EGFR expression was significantly associated with more advanced stage and higher grade. EGFR expression was different in luminal A-like (Lum A, 1.3%) versus luminal B-like (Lum B, 11.4%) subtypes. On multivariate analyses for survival Lum B subtype EGFR+ tumors showed a hazard ratio (HR) of 5.22 (95% CI, 1.29-21.15, P = 0.020) for overall survival (OS) and HR of 2.91 (95% CI, 1.35-6.28, P = 0.006) for disease-free survival (DFS). Levels of EGFR inversely correlated with ER-α expression. Basal ER-α level was completely blocked by TGFA or EGF treatment. With TGFA pretreatment, ER+ breast cancer cells were resistant to 4-hydroxytamoxifen (4-OHT). Conversely, downregulation of ER-α by TGFA was reversed by gefitinib with recovered sensitivity to 4-OHT. Tumorigenicity of EGFR and ER+ breast cancer cells was significantly decreased by combined tamoxifen and gefitinib. Conclusion: Aberrant EGFR expression was associated with poor prognosis in ER+ breast cancers, especially the Lum B subtype. Loss of ER by EGFR activation induced tamoxifen resistance. Therefore, EGFR could be a therapeutic target for overcoming recurrence of ER+ breast cancer with high EGFR expression.
Citation Format: Yisun Jeong, Soo Youn Bae, Daeun You, Seung Pil Jung, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Seok Won Kim, Jeong Eon Lee, Sangmin Kim, Seok Jin Nam. Epidermal growth factor receptor as therapeutic target in hormone receptor-positive breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-04-25.
Abstract P6-06-17: Assessment of TILs, PDL1 and FOXP3 expression in metaplastic breast cancer: A glimpse into its tumour microenvironment
Authors: Kalaw Emarene Mationg 
Published: March 2020

Abstract
BACKGROUND: Metaplastic breast carcinoma (MBC) encompasses a heterogeneous group of tumours that differentiate into squamous and/or spindle, chondroid, osseous or rhabdoid mesenchymal-looking elements.Tumour cells,among others in the tumour microenvironment express Program Death Ligand 1 (PD-L1); an emerging therapeutic target. Activation of PD-1/PD-L1 pathway in neoplastic cells results in dampening of immune response.FOXP3 is a transcriptional factor for regulatory T-cells associated with immunosuppression. AIMS:We aimed to evaluate the immunohistochemical expression of PD-L1, FOXP3 and tumour infiltrating lymphocytes (TILs) by assessing their expression in tumour and immune stromal cells and correlated this with patient outcome. METHODS:Quantification of TILs according to the 2014 working group was performed for a large cohort of MBC, and control Triple Negative breast cancer (TNBC) cohort. Expression of PD-L1 and FOXP3 was evaluated with immunohistochemistry. PD-L1 expression was recorded in the tumour cells and stromal TILS (sTILs). TILs in direct contact with malignant cells are classed intra-tumoural (iTILs),while sTILs are lymphocytes that do not interact directly with cancer cells. FOXP3 positive iTILs and sTILs were evaluated. Histologic score was calculated and findings compared with the TNBC cohort. RESULTS: No significant associations were found between TILs and World Health Organisation (WHO) MBC subtypes,or number and type of morphologies present in mixed MBCs. However, WHO MBC Types 1 and 4 tend to contain higher amounts of TILs, while WHO Type 6 presents with the least amount of infiltrate, suggesting a restricted immunogenic repertoire. Mixed MBC cases with more than 3 phenotypes present have fewer TILs. Low tumour and high sTILs PD-L1 expression displayed the best clinical outcome (without reaching significance in a Kaplan Meier survival analysis; p value= 0.5780) while FOXP3 iTILs is associated with adverse prognostic outcome (p value=0.0240). CONCLUSIONS: We identified a subset of patients that would likely respond to immunotherapeutics targeting the PD-1/PD-L1 checkpoint. We report the biological significance of FOXP3 and TILs in MBC; wherein, their presence establishes a potential prognostic value.
Citation Format: Emarene Mationg Kalaw. Assessment of TILs, PDL1 and FOXP3 expression in metaplastic breast cancer: A glimpse into its tumour microenvironment [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-06-17.
Abstract P6-06-18: Promyelocytic leukemia (PML) is induced by tumor-associated macrophages (TAMs) in breast cancer
Authors: Long Meijun , Yang Mei , An Jun , Liu Renbin 
Published: March 2020

Abstract
Introduction: Tumor-associated macrophages (TAMs) are pivotal orchestrators of the tumor microenvironment. Clinical evidences show that density of TAMs increases with lymph node metastasis, which is associated with poor prognosis in breast cancer patients. The underlying mechanism has not been clearly elucidated.
Methods: Transcriptome of MCF-7 cells cocultured with TAMs or monocyte-derived macrophages (MDMs) was analyzed and compared by RNA-seq analysis, which showed that the promyelocytic leukemia (PML) gene was significantly upregulated by TAMs (P&lt;0.001). The upregulation of PML was further verified by qRT-PCR and immunohistochemistry (IHC) in tissue microarrays (TMAs) containing 294 cases of breast cancer tissue with duplicate cores and 28 cases of normal breast tissue with single core. The age, sex, pathological type, histologic grade and stage of the patients were well recorded.
Results: RNA-seq analysis revealed that TAMs significantly upregulated PML expression, which was confirmed by qRT-PCR. Further, the protein level of PML was detected by IHC in TMAs. As expected, 57 cores of benign breast tissue, including normal breast tissue, adjacent normal breast tissue, adenosis and fibrous tissue in invasive ductal carcinoma (IDC) and lobular carcinoma in situ (LCIS), showed absent (80.70%) or low (19.30%) staining scores. In 508 (99.03%) cores of invasive breast cancer tissue, PML expression was positively correlated with lymph node metastasis (P= 0.003). However, no significant associations were observed between PML expression and tumor stage, primary tumor size, histologic tumor grade in IDC, or PML cellular localization.
Conclusion:Recently, PML, upregulated in a subset of breast cancer, has been identified as a breast cancer oncogene. Here, we demonstrated PML expression was induced by TAMs and positively correlated with lymph node metastasis. Thus, we conclude PML mediates TAMs function in breast tumorigenesis and TAMs stimulates the expression of PML in breast cancer.
Citation Format: Meijun Long, Mei Yang, Jun An, Renbin Liu. Promyelocytic leukemia (PML) is induced by tumor-associated macrophages (TAMs) in breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-06-18.
Abstract P6-07-03: The prognostic impact of HECTD1 E3 ubiquitin ligase expression in breast cancer patients
Authors: Uemoto Yasuaki , Kondo Naoto , Wanifuchi-Endo Yumi , Asano Tomoko , Hisada Tomoka , Nishikawa Sayaka , Katagiri Yusuke , Terada Mitsuo , Kato Akiko , Dong Yu , Kato Hiroyuki , Takahashi Satoru , Toyama Tatsuya 
Published: March 2020

Abstract
Background: The epithelial-to-mesenchymal transition (EMT) is fundamental and is required for cancer cells to metastasize. A E3 ubiquitin ligase, HECTD1,wasidentified as a potent regulator of EMT in breast cancer patients. Depletion of HECTD1 was reported to enhance EMT and migration. Here, we investigated the correlation of HECTD1 mRNA expression with prognosis in early breast cancer patients during long-term follow-up.
Materials and methods: A total of 627 invasive breast cancer tissues were analyzed for HECTD1 mRNA expression using a TaqMan PCR system. We also examined correlations between HECTD1 mRNA levels and clinicopathological factors in these samples. The median follow-up period was 10.2 years. Survival curves were analyzed using the Kaplan-Meier method. Cox proportional hazards regression analysis was used for univariate and multivariate analyses of prognostic values.
Results: We identified positive correlations between low HECTD1 mRNA levels and shorter disease-free survival (DFS) and overall survival (OS) in breast cancer patients (P=0.02 and P=0.03, respectively). Low HECTD1 mRNA levels were positively correlated with high tumor grade, ERα and PgR negativity, HER2 positivity, and type of adjuvant therapy. Univariate analysis indicated that low HECTD1 mRNA levels was a factor for poor DFS and OS in breast cancer patients (hazard ratio (HR), 1.43; 95% confidence interval (CI), 1.06-1.95 and HR, 1.49; 95% CI, 1.03-2.17, respectively) (Table 1).
Conclusion: We showed that low HECTD1 mRNA expression may be a predictive factor of poor prognosis in breast cancer patients. HECTD1 could therefore be a candidate biomarker and therapeutic target in breast cancer patients.
Table 1. Univariate Cox regression analysis of HECTD1 mRNA expression associated with prognosis.Patients (n=617)UnivariateDisease-free survivalOverall survivalp valueHR (95%CI)p valueHR (95%CI)HectD1 mRNA expressionhigh3130.021(Reference)0.031(Reference)low3141.43(1.06-1.95)1.49(1.03-2.17)
Citation Format: Yasuaki Uemoto, Naoto Kondo, Yumi Wanifuchi-Endo, Tomoko Asano, Tomoka Hisada, Sayaka Nishikawa, Yusuke Katagiri, Mitsuo Terada, Akiko Kato, Yu Dong, Hiroyuki Kato, Satoru Takahashi, Tatsuya Toyama. The prognostic impact of HECTD1 E3 ubiquitin ligase expression in breast cancer patients [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-07-03.